Treatment for Early, Uncomplicated Coccidioidomycosis: What Is Success?
AffiliationUniv Arizona, Coll Med, Valley Fever Ctr Excellence
Univ Arizona, Coll Med, Dept Med
MetadataShow full item record
PublisherOXFORD UNIV PRESS INC
CitationJohn N Galgiani, Janis E Blair, Neil M Ampel, George R Thompson, Treatment for Early, Uncomplicated Coccidioidomycosis: What Is Success?, Clinical Infectious Diseases, Volume 70, Issue 9, 1 May 2020, Pages 2008–2012, https://doi.org/10.1093/cid/ciz933
JournalCLINICAL INFECTIOUS DISEASES
RightsCopyright © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: firstname.lastname@example.org.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractThe care of primary pulmonary coccidioidomycosis remains challenging. Such infections produce a variety of signs, symptoms, and serologic responses that cause morbidity in patients and concern in treating clinicians for the possibility of extrapulmonary dissemination. Illness may be due to ongoing fungal growth that produces acute inflammatory responses, resulting in tissue damage and necrosis, and for this, administering an antifungal drug may be of benefit. In contrast, convalescence may be prolonged by other immunologic reactions to infection, even after fungal replication has been arrested, and in those situations, antifungal therapy is unlikely to yield clinical improvement. In this presentation, we discuss what findings are clinical indicators of fungal growth and what other sequelae are not. Understanding these differences provides a rational management strategy for deciding when to continue, discontinue, or reinstitute antifungal treatments.
Note12 month embargo; published online: 23 September 2019
VersionFinal accepted manuscript
- Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis.
- Authors: Blair JE, Chang YH, Cheng MR, Vaszar LT, Vikram HR, Orenstein R, Kusne S, Ho S, Seville MT, Parish JM
- Issue date: 2014 Jun
- Coccidioidomycosis Complement Fixation Titer Trends in the Age of Antifungals.
- Authors: McHardy IH, Dinh BN, Waldman S, Stewart E, Bays D, Pappagianis D, Thompson GR 3rd
- Issue date: 2018 Dec
- Treatment considerations in pulmonary coccidioidomycosis.
- Authors: Hartmann CA, Aye WT, Blair JE
- Issue date: 2016 Oct
- Pulmonary coccidioidomycosis.
- Authors: Spinello IM, Munoz A, Johnson RH
- Issue date: 2008 Apr
- Systemic fungal infections: diagnosis and treatment. I. Coccidioidomycosis.
- Authors: Knoper SR, Galgiani JN
- Issue date: 1988 Dec